Premature infants (delivery before 37 wk of gestation) admitted to the NICU at the University of Iowa Children's Hospital between 2000 and 2009 were recruited to examine preterm birth (PTB) and ...

Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

Serums have earned a starring role in modern skincare, and they’re praised for their ability to hydrate, brighten, smooth, ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

YARTEMLEA is approved by the U.S. FDA for the treatment of TA-TMA in adults and in children ages two years and older. A marketing authorization application for YARTEMLEA for TA-TMA is under review by ...

An evidence-based exploration of how culinary botanicals synergize with cannabinoids to create pharmacologically active, ...

Palantir Technologies Inc is turning a long running Silicon Valley debate into corporate policy, with Chief Executive Officer ...

Golden State head coach Steve Kerr has rationalized his decision to bench a pricey Warriors star two months into the 2025-26 ...

Alabama treasure hunters have a not-so-secret headquarters in Irondale, and it’s housed in a sprawling red and white building ...